About TamuroBio

TamuroBio is an early-stage biotech company with a mission to transform the lives of patients suffering from NASH, an area of unmet need as there are currently no FDA-approved therapeutics.

About TB-019

TB-019 is a novel approach for the treatment of NASH, with a unique mechanism of action targeting 4-HNE. TB-019 has demonstrated activity in both prevention and treatment of NASH in relevant pre-clinical studies.